Typhoid Treatment Market By Treatment type (Antibiotics, Pain Medication, Others), By Route of Administration (Oral, Intravenous), By Distribution Channel (Hospital Pharmacies, Drug stores and retail pharmacies, Online providers): Global Opportunity Analysis and Industry Forecast, 2023-2032

Typhoid Treatment Market

The typhoid treatment encompasses a range of products and services aimed at addressing this infectious disease, which is caused by Salmonella Typhi bacteria. The market addresses the growing demand for effective treatments due to the prevalence of typhoid, drug-resistant strains, and the need for medical solutions to combat this global public health concern. It includes both branded and generic medications, vaccines, diagnostics, and therapeutic approaches to manage and mitigate typhoid-related illnesses.

The typhoid treatment market is poised for significant growth due to several key factors that are shaping its landscape. One of the primary drivers is the growing prevalence of typhoid fever. According to an article published by Medscape in 2022, typhoid fever infects approximately 21.6 million people globally, with an incidence rate of 3.6 per 1,000 population. Furthermore, it causes an estimated 200,000 deaths annually.  Typhoid remains a major public health concern, and its continued prevalence creates a substantial demand for effective treatment options.

Moreover, the rise in drug-resistant typhoid cases has become a critical issue. Drug-resistant strains of Salmonella Typhi, the bacterium responsible for typhoid fever, have emerged, necessitating the development of more advanced and effective treatment solutions. This challenge fuels research and development efforts within the pharmaceutical industry, leading to the creation of novel antibiotics and alternative therapeutic approaches.

However, the availability of generic medications also plays a pivotal role in driving market growth. Generic drugs, which are often more affordable than their brand-name counterparts, improve accessibility to treatment for a broader population, especially in regions with limited healthcare resources. This increased accessibility can significantly expand the market's reach and demand.

Furthermore, the growing emphasis on guidelines for the responsible use of antibiotics in typhoid management is expected to influence the market. Antibiotic resistance is a global health crisis, and guidelines that promote judicious antibiotic use are crucial in combating this issue. As healthcare providers and organizations adhere to these guidelines, it is likely to drive the demand for specific antibiotics and treatment regimens that align with recommended practices.

Another crucial factor contributing to market growth is the surge in clinical trials for the development of new drugs. The pharmaceutical industry's commitment to research and innovation is yielding promising treatment options, providing hope for more effective and targeted therapies. Clinical trials are essential in assessing the safety and efficacy of these new treatments, paving the way for their eventual approval and commercialization. An example of such research is the clinical trial conducted by the Oxford University Clinical Research Unit in Vietnam. It is investigating the use of a combination therapy of azithromycin and cefixime for the treatment of typhoid fever. This research aims to evaluate the efficacy and safety of combination therapy in managing disease. 

In addition, the increasing urge for travel and tourism is anticipated to further boost the demand for typhoid treatments. Travelers, especially those visiting regions with a higher risk of typhoid, seek preventative measures and access to treatment options in case of infection. This trend is expected to result in a growing market for typhoid antibiotics, and diagnostics.

The global typhoid treatment market is segmented on the basis of treatment type, route of administration, distribution channel, and region. On the basis of treatment type, the market is classified into antibiotics, pain medication and others. The antibiotics segment is bifurcated into fluoroquinolones, macrolides, cephalosporins, and others. By route of administration; the market is divided into oral and intravenous. Depending on distribution channel, it is categorized into hospital pharmacies, drug stores and retail pharmacies, and online providers. Region-wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).

The report provides a comprehensive analysis of the key players that operate in the global typhoid treatment market such as Abbott Laboratories, Alkem Laboratories Ltd., Cipla Ltd., Bayer AG, Lupin Limited, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Limited, F. Hoffmann-La Roche Ltd. and Teva Pharmaceutical Industries Limited. Key players operating in the market have adopted funding and spin off as their key strategies to expand their product portfolio.

Key Market Insights

On the basis of treatment type, the antibiotics segment dominated the market and is expected to be the fastest-growing segment with a CAGR of 5.4% during the forecast period.

On the basis of route of administration, the intravenous segment dominated the market and is expected to be the fastest-growing segment with a CAGR of 5.8% during the forecast period.

On the basis of distribution channel, hospital pharmacies were the highest revenue contributor to the market and is estimated to reach $2530.95 million by 2032, with a CAGR of 4.7%. However, the online providers segment is estimated to be the fastest-growing segment with a CAGR of 6.4% during the forecast period.

Region wise, North America generated the largest revenue in 2022. However, Asia-Pacific is anticipated to grow at the highest CAGR of 6.7% during the forecast period.

Overview

The typhoid treatment market was valued at $2,898.64 million in 2022 and is estimated to reach $4,789.88 million by 2032, exhibiting a CAGR of 5.1% from 2023 to 2032. Typhoid, also known as typhoid fever, is a serious infectious disease caused by the bacterium salmonella enterica serovar typhi. It is primarily transmitted through contaminated food and water, and its symptoms include high fever, headache, abdominal pain, and gastrointestinal disturbances. In severe cases, it can lead to life-threatening complications if left untreated.

The treatment of typhoid involves the use of antibiotics to target and kill the Salmonella bacteria. Commonly prescribed antibiotics include fluoroquinolones, cephalosporins, and azithromycin. However, due to rise in antibiotic resistance, treatment choices may vary based on local resistance patterns and individual patient factors. Adequate hydration, rest, and a balanced diet are essential to support the body during recovery.

The growth of the typhoid treatment market is mainly attributed to a rise in prevalence of typhoid infections. For instance, according to Centers for Disease Control and Prevention (CDC) 2023, updated modeling study estimated 9.2 million typhoid fever cases and 110,000 deaths occurred globally, with the highest estimated incidence in the South-East Asian. In addition, growing population, urbanization, and lack of sanitization factors contribute to the increase in prevalence of typhoid infections. Thereby driving the market growth.

In addition, the increasing trend of global travel and tourism has become a significant contributing factor to the prevalence of typhoid infections, ultimately driving the growth of the typhoid treatment market. As people travel across international borders, they can unknowingly carry the Salmonella typhi bacteria, which causes typhoid fever, from one region to another. This cross-border transmission of the bacteria leads to the spread of typhoid to new areas, where it may not have been prevalent before.

Tourists and travelers often visit destinations with varying levels of hygiene and sanitation standards, including places with limited access to clean drinking water and proper sanitation facilities. In such locations, there is an increased risk of consuming contaminated food and water, which are primary sources of typhoid transmission. In addition, crowded tourist attractions and transportation hubs can facilitate the rapid transmission of the bacteria among travelers.

Moreover, advancements in antibiotic development play a crucial role in driving the growth of the typhoid treatment market. Further, continuous initiatives in R&D for discovery of new oral antibiotics with improved efficacy, expanded spectrum of activity, and reduced side effects drive the market growth. In addition, the growing focus on use of combinational antibiotics for the treatment of resistant typhi bacteria contributes in meeting the unmet medical needs and improve patient outcomes, thereby driving the market growth.

However, the typhoid treatment market faces certain restraints that may impede its growth and development. The emergence and spread of antibiotic resistance pose a significant challenge. Over time, bacteria can develop resistance to the antibiotics, making them less effective in treating infections. This necessitates the development of new antibiotics or alternative treatment options, which can be time-consuming and costly. In addition, stringent regulations and guidelines related to antibiotic use and its prescription contribute to the challenges in the development and market availability of antibiotics for typhoid treatment. This is expected to hinder market growth.

Furthermore, increasing awareness about the importance of timely and appropriate treatment for typhoid infections further drives market growth. Healthcare professionals and public health campaigns emphasizing the appropriate use of antibiotics also contribute to this awareness, thereby boosting the market demand and combating drug resistant typhi infections.

The typhoid treatment market is segmented on the basis of treatment type, route of administration, distribution channel, and region. On the basis of treatment type, the market is classified into antibiotics, pain medication and others. The antibiotics segment is bifurcated into fluoroquinolones, macrolides, cephalosporins, and others. By route of administration; the market is divided into oral and intravenous. Depending on distribution channel, it is categorized into hospital pharmacies, drug stores and retail pharmacies, and online providers. Region-wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).

Major players that operate in the market include Abbott Laboratories, Alkem Laboratories Ltd., Cipla Ltd., Bayer AG, Lupin Limited, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Limited, F. Hoffmann-La Roche Ltd. and Teva Pharmaceutical Industries Limited.

Key Benefits For Stakeholders

●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the typhoid treatment market analysis from 2022 to 2032 to identify the prevailing typhoid treatment market opportunities.

●The market research is offered along with information related to key drivers, restraints, and opportunities.

●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

●In-depth analysis of the typhoid treatment market segmentation assists to determine the prevailing market opportunities.

●Major countries in each region are mapped according to their revenue contribution to the global market.

●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

●The report includes the analysis of the regional as well as global typhoid treatment market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

● Quarterly Update and* (only available with a corporate license, on listed price)

● 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.

● Free Upcoming Version on the Purchase of Five and Enterprise User License.

● 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)

● 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 20% is equivalent to 3 working days of free work, applicable once)

● Free data Pack on the Five and Enterprise User License. (Excel version of the report)

● Free Updated report if the report is 6-12 months old or older.

● 24-hour priority response*

● Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline talk to the sales executive to know more)

● Go To Market Strategy

○ Pfizer Inc

Scope of Typhoid Treatment Market Report

1.1. Report description

1.2. Key market segments

1.3. Key benefits to the stakeholders

1.4. Research Methodology

1.4.1. Primary research

1.4.2. Secondary research

1.4.3. Analyst tools and models

2.1. CXO Perspective

3.1. Market definition and scope

3.2. Key findings

3.2.1. Top impacting factors

3.2.2. Top investment pockets

3.3. Porter’s five forces analysis

3.3.1. Moderate bargaining power of suppliers

3.3.2. Moderate threat of new entrants

3.3.3. Moderate threat of substitutes

3.3.4. Moderate intensity of rivalry

3.3.5. High bargaining power of buyers

3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Rise in prevalence of typhoid infectious

3.4.1.2. Availability of generic antibiotics

3.4.1.3. Rise in R&D activities

3.4.2. Restraints

3.4.2.1. Development of antibiotic resistance

3.4.2.2. Time consuming approvals

3.4.3. Opportunities

3.4.3.1. Growth opportunity in emerging markets

4.1. Overview

4.1.1. Market size and forecast

4.2. Antibiotics

4.2.1. Key market trends, growth factors and opportunities

4.2.2. Market size and forecast, by region

4.2.3. Market share analysis by country

4.2.4. Antibiotics Typhoid Treatment Market by Type

4.3. Pain Medication

4.3.1. Key market trends, growth factors and opportunities

4.3.2. Market size and forecast, by region

4.3.3. Market share analysis by country

4.4. Others

4.4.1. Key market trends, growth factors and opportunities

4.4.2. Market size and forecast, by region

4.4.3. Market share analysis by country

5.1. Overview

5.1.1. Market size and forecast

5.2. Oral

5.2.1. Key market trends, growth factors and opportunities

5.2.2. Market size and forecast, by region

5.2.3. Market share analysis by country

5.3. Intravenous

5.3.1. Key market trends, growth factors and opportunities

5.3.2. Market size and forecast, by region

5.3.3. Market share analysis by country

6.1. Overview

6.1.1. Market size and forecast

6.2. Hospital Pharmacies

6.2.1. Key market trends, growth factors and opportunities

6.2.2. Market size and forecast, by region

6.2.3. Market share analysis by country

6.3. Drug stores and retail pharmacies

6.3.1. Key market trends, growth factors and opportunities

6.3.2. Market size and forecast, by region

6.3.3. Market share analysis by country

6.4. Online providers

6.4.1. Key market trends, growth factors and opportunities

6.4.2. Market size and forecast, by region

6.4.3. Market share analysis by country

7.1. Overview

7.1.1. Market size and forecast By Region

7.2. North America

7.2.1. Key market trends, growth factors and opportunities

7.2.2. Market size and forecast, by Treatment type

7.2.3. Market size and forecast, by Route of Administration

7.2.4. Market size and forecast, by Distribution Channel

7.2.5. Market size and forecast, by country

7.2.5.1. U.S.

7.2.5.1.1. Market size and forecast, by Treatment type

7.2.5.1.2. Market size and forecast, by Route of Administration

7.2.5.1.3. Market size and forecast, by Distribution Channel

7.2.5.2. Canada

7.2.5.2.1. Market size and forecast, by Treatment type

7.2.5.2.2. Market size and forecast, by Route of Administration

7.2.5.2.3. Market size and forecast, by Distribution Channel

7.2.5.3. Mexico

7.2.5.3.1. Market size and forecast, by Treatment type

7.2.5.3.2. Market size and forecast, by Route of Administration

7.2.5.3.3. Market size and forecast, by Distribution Channel

7.3. Europe

7.3.1. Key market trends, growth factors and opportunities

7.3.2. Market size and forecast, by Treatment type

7.3.3. Market size and forecast, by Route of Administration

7.3.4. Market size and forecast, by Distribution Channel

7.3.5. Market size and forecast, by country

7.3.5.1. Germany

7.3.5.1.1. Market size and forecast, by Treatment type

7.3.5.1.2. Market size and forecast, by Route of Administration

7.3.5.1.3. Market size and forecast, by Distribution Channel

7.3.5.2. France

7.3.5.2.1. Market size and forecast, by Treatment type

7.3.5.2.2. Market size and forecast, by Route of Administration

7.3.5.2.3. Market size and forecast, by Distribution Channel

7.3.5.3. UK

7.3.5.3.1. Market size and forecast, by Treatment type

7.3.5.3.2. Market size and forecast, by Route of Administration

7.3.5.3.3. Market size and forecast, by Distribution Channel

7.3.5.4. Italy

7.3.5.4.1. Market size and forecast, by Treatment type

7.3.5.4.2. Market size and forecast, by Route of Administration

7.3.5.4.3. Market size and forecast, by Distribution Channel

7.3.5.5. Spain

7.3.5.5.1. Market size and forecast, by Treatment type

7.3.5.5.2. Market size and forecast, by Route of Administration

7.3.5.5.3. Market size and forecast, by Distribution Channel

7.3.5.6. Rest of Europe

7.3.5.6.1. Market size and forecast, by Treatment type

7.3.5.6.2. Market size and forecast, by Route of Administration

7.3.5.6.3. Market size and forecast, by Distribution Channel

7.4. Asia-Pacific

7.4.1. Key market trends, growth factors and opportunities

7.4.2. Market size and forecast, by Treatment type

7.4.3. Market size and forecast, by Route of Administration

7.4.4. Market size and forecast, by Distribution Channel

7.4.5. Market size and forecast, by country

7.4.5.1. Japan

7.4.5.1.1. Market size and forecast, by Treatment type

7.4.5.1.2. Market size and forecast, by Route of Administration

7.4.5.1.3. Market size and forecast, by Distribution Channel

7.4.5.2. China

7.4.5.2.1. Market size and forecast, by Treatment type

7.4.5.2.2. Market size and forecast, by Route of Administration

7.4.5.2.3. Market size and forecast, by Distribution Channel

7.4.5.3. Australia

7.4.5.3.1. Market size and forecast, by Treatment type

7.4.5.3.2. Market size and forecast, by Route of Administration

7.4.5.3.3. Market size and forecast, by Distribution Channel

7.4.5.4. India

7.4.5.4.1. Market size and forecast, by Treatment type

7.4.5.4.2. Market size and forecast, by Route of Administration

7.4.5.4.3. Market size and forecast, by Distribution Channel

7.4.5.5. South Korea

7.4.5.5.1. Market size and forecast, by Treatment type

7.4.5.5.2. Market size and forecast, by Route of Administration

7.4.5.5.3. Market size and forecast, by Distribution Channel

7.4.5.6. Rest of Asia-Pacific

7.4.5.6.1. Market size and forecast, by Treatment type

7.4.5.6.2. Market size and forecast, by Route of Administration

7.4.5.6.3. Market size and forecast, by Distribution Channel

7.5. LAMEA

7.5.1. Key market trends, growth factors and opportunities

7.5.2. Market size and forecast, by Treatment type

7.5.3. Market size and forecast, by Route of Administration

7.5.4. Market size and forecast, by Distribution Channel

7.5.5. Market size and forecast, by country

7.5.5.1. Brazil

7.5.5.1.1. Market size and forecast, by Treatment type

7.5.5.1.2. Market size and forecast, by Route of Administration

7.5.5.1.3. Market size and forecast, by Distribution Channel

7.5.5.2. Saudi Arabia

7.5.5.2.1. Market size and forecast, by Treatment type

7.5.5.2.2. Market size and forecast, by Route of Administration

7.5.5.2.3. Market size and forecast, by Distribution Channel

7.5.5.3. South Africa

7.5.5.3.1. Market size and forecast, by Treatment type

7.5.5.3.2. Market size and forecast, by Route of Administration

7.5.5.3.3. Market size and forecast, by Distribution Channel

7.5.5.4. Rest of LAMEA

7.5.5.4.1. Market size and forecast, by Treatment type

7.5.5.4.2. Market size and forecast, by Route of Administration

7.5.5.4.3. Market size and forecast, by Distribution Channel

8.1. Introduction

8.2. Top winning strategies

8.3. Product Mapping of Top 10 Player

8.4. Competitive Dashboard

8.5. Competitive Heatmap

8.6. Top player positioning, 2022

9.1. Alkem Laboratories Ltd.

9.1.1. Company overview

9.1.2. Key Executives

9.1.3. Company snapshot

9.1.4. Operating business segments

9.1.5. Product portfolio

9.1.6. Business performance

9.2. Lupin

9.2.1. Company overview

9.2.2. Key Executives

9.2.3. Company snapshot

9.2.4. Operating business segments

9.2.5. Product portfolio

9.2.6. Business performance

9.3. Abbott Laboratories

9.3.1. Company overview

9.3.2. Key Executives

9.3.3. Company snapshot

9.3.4. Operating business segments

9.3.5. Product portfolio

9.3.6. Business performance

9.4. SUN PHARMACEUTICAL INDUSTRIES LIMITED

9.4.1. Company overview

9.4.2. Key Executives

9.4.3. Company snapshot

9.4.4. Operating business segments

9.4.5. Product portfolio

9.4.6. Business performance

9.5. Novartis AG

9.5.1. Company overview

9.5.2. Key Executives

9.5.3. Company snapshot

9.5.4. Operating business segments

9.5.5. Product portfolio

9.5.6. Business performance

9.5.7. Key strategic moves and developments

9.6. Pfizer Inc.

9.6.1. Company overview

9.6.2. Key Executives

9.6.3. Company snapshot

9.6.4. Operating business segments

9.6.5. Product portfolio

9.6.6. Business performance

9.7. Teva Pharmaceutical Industries Limited

9.7.1. Company overview

9.7.2. Key Executives

9.7.3. Company snapshot

9.7.4. Operating business segments

9.7.5. Product portfolio

9.7.6. Business performance

9.7.7. Key strategic moves and developments

9.8. Cipla Ltd.

9.8.1. Company overview

9.8.2. Key Executives

9.8.3. Company snapshot

9.8.4. Operating business segments

9.8.5. Product portfolio

9.8.6. Business performance

9.9. Bayer AG

9.9.1. Company overview

9.9.2. Key Executives

9.9.3. Company snapshot

9.9.4. Operating business segments

9.9.5. Product portfolio

9.9.6. Business performance

9.10. F. Hoffmann-La Roche Ltd.

9.10.1. Company overview

9.10.2. Key Executives

9.10.3. Company snapshot

9.10.4. Operating business segments

9.10.5. Product portfolio

9.10.6. Business performanc

LIST OF TABLES

TABLE 01. GLOBAL TYPHOID TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)

TABLE 02. TYPHOID TREATMENT MARKET FOR ANTIBIOTICS, BY REGION, 2022-2032 ($MILLION)

TABLE 03. GLOBAL ANTIBIOTICS TYPHOID TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 04. TYPHOID TREATMENT MARKET FOR PAIN MEDICATION, BY REGION, 2022-2032 ($MILLION)

TABLE 05. TYPHOID TREATMENT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)

TABLE 06. GLOBAL TYPHOID TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 07. TYPHOID TREATMENT MARKET FOR ORAL, BY REGION, 2022-2032 ($MILLION)

TABLE 08. TYPHOID TREATMENT MARKET FOR INTRAVENOUS, BY REGION, 2022-2032 ($MILLION)

TABLE 09. GLOBAL TYPHOID TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 10. TYPHOID TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)

TABLE 11. TYPHOID TREATMENT MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)

TABLE 12. TYPHOID TREATMENT MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)

TABLE 13. TYPHOID TREATMENT MARKET, BY REGION, 2022-2032 ($MILLION)

TABLE 14. NORTH AMERICA TYPHOID TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)

TABLE 15. NORTH AMERICA TYPHOID TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 16. NORTH AMERICA TYPHOID TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 17. NORTH AMERICA TYPHOID TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 18. U.S. TYPHOID TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)

TABLE 19. U.S. TYPHOID TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 20. U.S. TYPHOID TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 21. CANADA TYPHOID TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)

TABLE 22. CANADA TYPHOID TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 23. CANADA TYPHOID TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 24. MEXICO TYPHOID TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)

TABLE 25. MEXICO TYPHOID TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 26. MEXICO TYPHOID TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 27. EUROPE TYPHOID TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)

TABLE 28. EUROPE TYPHOID TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 29. EUROPE TYPHOID TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 30. EUROPE TYPHOID TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 31. GERMANY TYPHOID TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)

TABLE 32. GERMANY TYPHOID TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 33. GERMANY TYPHOID TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 34. FRANCE TYPHOID TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)

TABLE 35. FRANCE TYPHOID TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 36. FRANCE TYPHOID TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 37. UK TYPHOID TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)

TABLE 38. UK TYPHOID TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 39. UK TYPHOID TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 40. ITALY TYPHOID TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)

TABLE 41. ITALY TYPHOID TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 42. ITALY TYPHOID TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 43. SPAIN TYPHOID TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)

TABLE 44. SPAIN TYPHOID TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 45. SPAIN TYPHOID TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 46. REST OF EUROPE TYPHOID TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)

TABLE 47. REST OF EUROPE TYPHOID TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 48. REST OF EUROPE TYPHOID TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 49. ASIA-PACIFIC TYPHOID TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)

TABLE 50. ASIA-PACIFIC TYPHOID TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 51. ASIA-PACIFIC TYPHOID TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 52. ASIA-PACIFIC TYPHOID TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 53. JAPAN TYPHOID TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)

TABLE 54. JAPAN TYPHOID TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 55. JAPAN TYPHOID TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 56. CHINA TYPHOID TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)

TABLE 57. CHINA TYPHOID TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 58. CHINA TYPHOID TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 59. AUSTRALIA TYPHOID TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)

TABLE 60. AUSTRALIA TYPHOID TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 61. AUSTRALIA TYPHOID TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 62. INDIA TYPHOID TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)

TABLE 63. INDIA TYPHOID TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 64. INDIA TYPHOID TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 65. SOUTH KOREA TYPHOID TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)

TABLE 66. SOUTH KOREA TYPHOID TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 67. SOUTH KOREA TYPHOID TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 68. REST OF ASIA-PACIFIC TYPHOID TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)

TABLE 69. REST OF ASIA-PACIFIC TYPHOID TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 70. REST OF ASIA-PACIFIC TYPHOID TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 71. LAMEA TYPHOID TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)

TABLE 72. LAMEA TYPHOID TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 73. LAMEA TYPHOID TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 74. LAMEA TYPHOID TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 75. BRAZIL TYPHOID TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)

TABLE 76. BRAZIL TYPHOID TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 77. BRAZIL TYPHOID TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 78. SAUDI ARABIA TYPHOID TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)

TABLE 79. SAUDI ARABIA TYPHOID TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 80. SAUDI ARABIA TYPHOID TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 81. SOUTH AFRICA TYPHOID TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)

TABLE 82. SOUTH AFRICA TYPHOID TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 83. SOUTH AFRICA TYPHOID TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 84. REST OF LAMEA TYPHOID TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)

TABLE 85. REST OF LAMEA TYPHOID TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 86. REST OF LAMEA TYPHOID TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 87. ALKEM LABORATORIES LTD.: KEY EXECUTIVES

TABLE 88. ALKEM LABORATORIES LTD.: COMPANY SNAPSHOT

TABLE 89. ALKEM LABORATORIES LTD.: PRODUCT SEGMENTS

TABLE 90. ALKEM LABORATORIES LTD.: PRODUCT PORTFOLIO

TABLE 91. LUPIN: KEY EXECUTIVES

TABLE 92. LUPIN: COMPANY SNAPSHOT

TABLE 93. LUPIN: PRODUCT SEGMENTS

TABLE 94. LUPIN: PRODUCT PORTFOLIO

TABLE 95. ABBOTT LABORATORIES: KEY EXECUTIVES

TABLE 96. ABBOTT LABORATORIES: COMPANY SNAPSHOT

TABLE 97. ABBOTT LABORATORIES: PRODUCT SEGMENTS

TABLE 98. ABBOTT LABORATORIES: PRODUCT PORTFOLIO

TABLE 99. SUN PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES

TABLE 100. SUN PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT

TABLE 101. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS

TABLE 102. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO

TABLE 103. NOVARTIS AG: KEY EXECUTIVES

TABLE 104. NOVARTIS AG: COMPANY SNAPSHOT

TABLE 105. NOVARTIS AG: PRODUCT SEGMENTS

TABLE 106. NOVARTIS AG: PRODUCT PORTFOLIO

TABLE 107. NOVARTIS AG: KEY STRATERGIES

TABLE 108. PFIZER INC.: KEY EXECUTIVES

TABLE 109. PFIZER INC.: COMPANY SNAPSHOT

TABLE 110. PFIZER INC.: PRODUCT SEGMENTS

TABLE 111. PFIZER INC.: PRODUCT PORTFOLIO

TABLE 112. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES

TABLE 113. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT

TABLE 114. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS

TABLE 115. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO

TABLE 116. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY STRATERGIES

TABLE 117. CIPLA LTD.: KEY EXECUTIVES

TABLE 118. CIPLA LTD.: COMPANY SNAPSHOT

TABLE 119. CIPLA LTD.: PRODUCT SEGMENTS

TABLE 120. CIPLA LTD.: PRODUCT PORTFOLIO

TABLE 121. BAYER AG: KEY EXECUTIVES

TABLE 122. BAYER AG: COMPANY SNAPSHOT

TABLE 123. BAYER AG: PRODUCT SEGMENTS

TABLE 124. BAYER AG: PRODUCT PORTFOLIO

TABLE 125. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES

TABLE 126. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT

TABLE 127. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS

TABLE 128. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO LIST OF FIGURES

FIGURE 01. TYPHOID TREATMENT MARKET, 2022-2032

FIGURE 02. SEGMENTATION OF TYPHOID TREATMENT MARKET,2022-2032

FIGURE 03. TOP INVESTMENT POCKETS IN TYPHOID TREATMENT MARKET (2023-2032)

FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS

FIGURE 05. MODERATE THREAT OF NEW ENTRANTS

FIGURE 06. MODERATE THREAT OF SUBSTITUTES

FIGURE 07. MODERATE INTENSITY OF RIVALRY

FIGURE 08. HIGH BARGAINING POWER OF BUYERS

FIGURE 09. GLOBAL TYPHOID TREATMENT MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES

FIGURE 10. TYPHOID TREATMENT MARKET, BY TREATMENT TYPE, 2022 AND 2032(%)

FIGURE 11. COMPARATIVE SHARE ANALYSIS OF TYPHOID TREATMENT MARKET FOR ANTIBIOTICS, BY COUNTRY 2022 AND 2032(%)

FIGURE 12. COMPARATIVE SHARE ANALYSIS OF TYPHOID TREATMENT MARKET FOR PAIN MEDICATION, BY COUNTRY 2022 AND 2032(%)

FIGURE 13. COMPARATIVE SHARE ANALYSIS OF TYPHOID TREATMENT MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)

FIGURE 14. TYPHOID TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022 AND 2032(%)

FIGURE 15. COMPARATIVE SHARE ANALYSIS OF TYPHOID TREATMENT MARKET FOR ORAL, BY COUNTRY 2022 AND 2032(%)

FIGURE 16. COMPARATIVE SHARE ANALYSIS OF TYPHOID TREATMENT MARKET FOR INTRAVENOUS, BY COUNTRY 2022 AND 2032(%)

FIGURE 17. TYPHOID TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022 AND 2032(%)

FIGURE 18. COMPARATIVE SHARE ANALYSIS OF TYPHOID TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)

FIGURE 19. COMPARATIVE SHARE ANALYSIS OF TYPHOID TREATMENT MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)

FIGURE 20. COMPARATIVE SHARE ANALYSIS OF TYPHOID TREATMENT MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2022 AND 2032(%)

FIGURE 21. TYPHOID TREATMENT MARKET BY REGION, 2022 AND 2032(%)

FIGURE 22. U.S. TYPHOID TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 23. CANADA TYPHOID TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 24. MEXICO TYPHOID TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 25. GERMANY TYPHOID TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 26. FRANCE TYPHOID TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 27. UK TYPHOID TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 28. ITALY TYPHOID TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 29. SPAIN TYPHOID TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 30. REST OF EUROPE TYPHOID TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 31. JAPAN TYPHOID TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 32. CHINA TYPHOID TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 33. AUSTRALIA TYPHOID TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 34. INDIA TYPHOID TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 35. SOUTH KOREA TYPHOID TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 36. REST OF ASIA-PACIFIC TYPHOID TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 37. BRAZIL TYPHOID TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 38. SAUDI ARABIA TYPHOID TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 39. SOUTH AFRICA TYPHOID TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 40. REST OF LAMEA TYPHOID TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 41. TOP WINNING STRATEGIES, BY YEAR (2020-2022)

FIGURE 42. TOP WINNING STRATEGIES, BY DEVELOPMENT (2020-2022)

FIGURE 43. TOP WINNING STRATEGIES, BY COMPANY (2020-2022)

FIGURE 44. PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 45. COMPETITIVE DASHBOARD

FIGURE 46. COMPETITIVE HEATMAP: TYPHOID TREATMENT MARKET

FIGURE 47. TOP PLAYER POSITIONING, 2022

FIGURE 48. ALKEM LABORATORIES LTD.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 49. ALKEM LABORATORIES LTD.: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 50. LUPIN: NET SALES, 2020-2022 ($MILLION)

FIGURE 51. LUPIN: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 52. ABBOTT LABORATORIES: NET SALES, 2020-2022 ($MILLION)

FIGURE 53. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 54. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 55. SUN PHARMACEUTICAL INDUSTRIES LIMITED: SALES REVENUE, 2020-2022 ($MILLION)

FIGURE 56. SUN PHARMACEUTICAL INDUSTRIES LIMITED: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 57. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)

FIGURE 58. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 59. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 60. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 61. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 62. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 63. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 64. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 65. CIPLA LTD.: SALES REVENUE, 2020-2022 ($MILLION)

FIGURE 66. CIPLA LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 67. CIPLA LTD.: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 68. F. HOFFMANN-LA ROCHE LTD.: SALES REVENUE, 2020-2022 ($MILLION)

FIGURE 69. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%